mecasermin: Clinical Trials

7 trials of mecasermin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 terminated. 7 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 37Completed 5, Terminated 2
Phase 23Completed 2, Terminated 1

Follow mecasermin: new trials by email Literature Review of mecasermin trials Research Report on mecasermin

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effects of Anorexia Nervosa on Peak Bone Mass
RhIGF-1 with transdermal 17-beta estradiol, Placebo and transdermal 17-beta estradiol - Anorexia Nervosa
Phase 3CompletedMassachusetts General Hospital752011-02-012021-07-13
Metabolic Effects of GH and IGF-I in Growth Hormone Deficient(GHD) and Diabetes and Impaired Glucose Tolerance(IGT)
NutropinAq (GH) and Increlex (IGF-I), NutropinAq and placebo - Diabetes
Phase 3CompletedKarolinska University Hospital142009-10-012015-04-07
Effect of Increlex® on Children With Crohn Disease
rhIGF (Increlex) - Crohn Disease
Phase 2 / Phase 3TerminatedNationwide Children's Hospital32008-10-012018-03-02
Treatment of Children and Adolescents With Growth Failure Associated With Primary IGF-1 Deficiency
rh IGF-1 (mecasermin) - Growth Disorders
Phase 3TerminatedIpsen1142005-11-012020-08-14
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
rhIGF-1 (mecasermin) for a period of 86 weeks - Insulin-Like Growth Factor-1 Deficiency, Growth Disorders
Phase 2 / Phase 3CompletedIpsen452005-07-012020-07-27
Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency
rhIGF-1 (mecasermin, Tercica, Inc.) - Growth Disorders, Insulin-Like Growth Factor-1 Deficiency
Phase 3CompletedIpsen1372004-03-012019-09-18
Long-Term Treatment With rhIGF-1 in GHIS
mecasermin - Growth Hormone Insensitivity Syndrome
Phase 2 / Phase 3CompletedIpsen921991-05-202023-07-06

Conditions studied

Growth Disorders (3)  ·  Anorexia Nervosa (1)  ·  Crohn Disease (1)  ·  Diabetes Mellitus (1)  ·  Dwarfism (1)  ·  Dwarfism, Pituitary (1)  ·  Inflammatory Bowel Diseases (1)  ·  Laron Syndrome (1)

Sponsors

Ipsen (4)  ·  Karolinska University Hospital (1)  ·  Massachusetts General Hospital (1)  ·  Nationwide Children's Hospital (1)

Countries

United States (5)  ·  France (1)  ·  Sweden (1)

Top investigators

Charlotte Hoeybye, MD (1)  ·  Dana S. Hardin, MD (1)  ·  Madhusmita Misra, MD, MPH (1)  ·  Sr Vice President, Clinical Development and Medical Affairs (1)

Results publications

PMID 17192294

NIH funding

2019 (3)